Filings & corporate actions
73 results filed
CSVNext results · Q2 FY27
Expected 29 Oct 2026 – 10 Nov 2026
Estimate: filed 29–41 days after quarter end, last 5 times
Dividend
₹34.00 per share · last 24 Jul 2026
2026
- 5 AugresultsResults · Q1 FY27 · consolidated and standalone+8.0%NSE
- 24 JuldividendDividend · ₹34.00 per share+0.6%
- 20 JulshareholdingShareholding · 30 Jun 2026+2.8%NSE
- 12 MayresultsResults · Q4 FY26 · consolidated and standalone-3.0%NSE
- 11 AprshareholdingShareholding · 31 Mar 2026-2.9%NSE
- 9 FebresultsResults · Q3 FY26 · consolidated and standalone-2.8%NSE
- 7 JanshareholdingShareholding · 31 Dec 2025+4.3%NSE
Reaction to results · all yearsrose on day 0 in 24 of 72 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 5 Aug 2026 | +8.0% | +16.3% | +14.7% | 27.0× |
| Q4 FY26 | 12 May 2026 | -3.0% | -2.2% | -0.2% | 7.8× |
| Q3 FY26 | 9 Feb 2026 | -2.8% | -1.6% | -7.6% | 4.3× |
| Q2 FY26 | 7 Nov 2025 | +1.5% | -2.7% | -9.9% | 10.2× |
| Q1 FY26 | 31 Jul 2025 | -2.0% | -1.4% | +3.4% | 1.9× |
| Q4 FY25 | 15 May 2025 | -6.8% | -5.9% | +11.2% | 6.8× |
| Q3 FY25 | 10 Feb 2025 | -6.9% | -24.8% | -25.3% | 2.9× |
| Q2 FY25 | 6 Nov 2024 | -10.7% | -7.5% | +11.0% | 5.4× |
| Q1 FY25 | 1 Aug 2024 | +18.1% | +22.8% | +33.5% | 13.1× |
| Q4 FY24 | 10 May 2024 | -15.1% | -12.8% | -12.1% | 4.4× |
| Q3 FY24 | 8 Feb 2024 | +3.7% | +9.5% | 0.0% | 2.9× |
| Q2 FY24 | 7 Nov 2023 | +7.0% | +14.9% | +10.1% | 6.0× |
| Q1 FY24 | 3 Aug 2023 | +5.3% | +15.6% | +2.1% | 2.4× |
| Q4 FY23 | 11 May 2023 | +1.7% | +11.6% | +10.7% | 7.1× |
| Q3 FY23 | 13 Feb 2023 | +13.3% | +16.3% | +19.8% | 15.9× |
| Q2 FY23 | 10 Nov 2022 | +5.7% | +6.0% | -4.5% | 9.5× |
| Q1 FY23 | 3 Aug 2022 | -7.8% | -6.5% | +3.3% | 4.3× |
| Q4 FY22 | 11 May 2022 | -14.5% | -16.2% | -13.3% | 1.6× |
| Q3 FY22 | 1 Feb 2022 | -5.6% | -10.3% | -28.0% | 4.5× |
| Q2 FY22 | 29 Oct 2021 | +5.0% | +4.8% | +9.8% | 1.4× |
| Q1 FY22 | 3 Aug 2021 | -5.0% | -13.9% | -12.4% | 0.8× |
| Q4 FY21 | 11 May 2021 | -10.0% | -9.8% | -17.7% | 4.4× |
| Q3 FY21 | 2 Feb 2021 | +4.3% | +44.0% | +43.5% | 2.6× |
| Q2 FY21 | 3 Nov 2020 | -4.9% | -14.4% | -13.2% | 1.5× |
| Q1 FY21 | 4 Aug 2020 | -8.9% | -6.8% | +9.2% | 5.4× |
| Q4 FY20 | 22 May 2020 | -5.9% | -11.5% | +18.8% | 3.0× |
| Q3 FY20 | 11 Feb 2020 | -0.7% | -8.9% | -33.4% | 9.8× |
| Q2 FY20 | 14 Nov 2019 | -4.4% | -9.1% | -21.5% | 11.0× |
| Q1 FY20 | 13 Aug 2019 | +5.2% | -2.9% | +5.6% | 19.7× |
| Q4 FY19 | 16 May 2019 | -6.5% | -13.8% | -22.6% | 1.9× |
| Q3 FY19 | 19 Feb 2019 | -1.3% | +37.6% | +19.6% | 0.1× |
| Q2 FY19 | 4 Dec 2018 | -1.4% | -7.2% | +3.7% | 0.4× |
| Q1 FY19 | 27 Aug 2018 | +0.2% | +10.2% | +0.1% | 0.2× |
| Q4 FY18 | 19 Jun 2018 | +0.2% | -2.4% | -12.0% | 1.2× |
| Q3 FY18 | 9 Feb 2018 | -0.7% | +0.9% | +0.2% | 0.4× |
| Q2 FY18 | 23 Nov 2017 | -10.8% | -23.7% | -30.1% | 2.5× |
| Q1 FY18 | 22 Sept 2017 | -4.2% | -6.3% | +5.3% | 0.4× |
| Q4 FY17 | 16 May 2017 | 0.0% | +7.2% | +3.4% | 0.1× |
| Q3 FY17 | 11 Feb 2017 | +1.4% | -0.1% | +26.8% | 2.0× |
| Q2 FY17 | 9 Nov 2016 | -2.3% | -5.5% | -1.0% | 1.9× |
| Q1 FY17 | 13 Aug 2016 | 0.0% | +14.1% | +9.2% | 1.8× |
| Q4 FY16 | 23 May 2016 | -4.4% | +2.0% | +4.5% | 0.5× |
| Q3 FY16 | 5 Feb 2016 | -0.9% | -16.2% | -14.2% | 0.5× |
| Q2 FY16 | 6 Nov 2015 | +3.0% | +3.5% | +0.9% | 0.6× |
| Q1 FY16 | 16 Aug 2015 | +9.9% | -1.5% | +36.6% | 7.3× |
| Q4 FY15 | 8 May 2015 | +1.3% | +2.2% | -3.2% | 0.7× |
| Q3 FY15 | 31 Jan 2015 | -20.0% | -30.5% | -30.8% | 10.1× |
| Q2 FY15 | 31 Oct 2014 | -1.0% | -10.5% | -7.5% | 0.4× |
| Q1 FY15 | 1 Aug 2014 | -3.5% | -15.6% | +7.9% | 2.0× |
| Q4 FY14 | 9 May 2014 | -11.0% | -20.2% | -6.8% | 1.9× |
| Q3 FY14 | 6 Feb 2014 | +0.5% | -7.5% | -10.8% | 1.0× |
| Q2 FY14 | 9 Nov 2013 | +4.2% | +7.5% | +9.3% | 3.3× |
| Q1 FY14 | 6 Aug 2013 | -3.0% | +9.1% | -7.5% | 0.1× |
| Q4 FY13 | 22 May 2013 | -3.6% | -4.9% | -10.0% | 0.4× |
| Q3 FY13 | 14 Feb 2013 | -3.8% | -9.1% | -19.4% | 0.2× |
| Q2 FY13 | 20 Nov 2012 | -4.2% | -2.2% | -3.1% | 0.6× |
| Q1 FY13 | 13 Aug 2012 | -2.0% | +2.6% | +27.5% | 0.6× |
| Q4 FY12 | 4 May 2012 | +5.0% | +8.9% | +9.8% | 0.4× |
| Q3 FY12 | 10 Feb 2012 | -3.8% | -8.6% | -8.6% | 4.9× |
| Q2 FY12 | 3 Nov 2011 | -2.6% | -8.9% | -7.5% | 0.6× |
| Q1 FY12 | 5 Aug 2011 | -2.2% | -9.2% | -12.5% | 1.0× |
| Q4 FY11 | 20 May 2011 | -1.1% | -1.6% | -2.5% | 2.5× |
| Q3 FY11 | 2 Feb 2011 | +5.0% | -0.4% | +6.8% | 1.4× |
| Q2 FY11 | 29 Oct 2010 | -1.3% | -6.8% | -18.7% | 1.2× |
| Q1 FY11 | 29 Jul 2010 | -3.1% | -3.8% | -4.5% | 0.8× |
| Q4 FY10 | 29 May 2010 | -5.7% | -8.2% | -0.8% | 0.5× |
| Q3 FY10 | 28 Jan 2010 | -4.5% | -11.0% | -13.0% | 1.1× |
| Q2 FY10 | 20 Oct 2009 | +0.1% | -15.8% | -17.3% | 42.2× |
| Q1 FY10 | 18 Jul 2009 | -9.4% | -15.1% | -16.3% | 3.6× |
| Q4 FY09 | 21 May 2009 | +3.4% | -4.9% | -10.5% | 8.5× |
| Q3 FY09 | 22 Jan 2009 | -11.3% | -9.0% | -12.3% | 1.3× |
| Q2 FY09 | 24 Oct 2008 | -13.7% | +1.4% | -3.4% | — |
| Average | -2.0% | -2.5% | -1.8% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+119.2%
Profit YoY+962.4%
Interest cost YoY+157.9%
Revenue QoQ-17.3%
Profit QoQ-30.6%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +20.4% | +21.2% | +25.0% | +20.5% | +20.2% | — |
| Profit | +21.7% | +32.2% | +66.3% | +46.3% | +63.9% | — |
Key data
CSVOpen21,940.00
Day range21,410.00 – 21,975.00
52-week range11,500.00 – 24,225.00
From 52w high-9.6%
RSI (14)45.8
ATR (14)718.40
Volume61.8K
Avg volume (20D)52.1K
Rel volume1.19×
Volatility (1Y)37.9%
Turnover₹135.4Cr
SMA 50 / 20022,203.32 / 17,015.62
Delivery percentage
Latest · 6 Oct 202651.0%
20-day avg48.6%
1-year avg37.6%
Percentile (own history)56th
Range6.2–100.0%
Sessions1,731
Over the last 20 sessions NEULANDLAB settled 48.6% of its traded quantity, which is above average for an NSE equity. Its one-year average is 37.6%, so recent sessions are running 11.0 points higher than usual. The latest session ranks higher than 56% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +0.14% | +2.17% | -4.30% | +15.90% | +76.18% | +56.85% |
Valuation
CSVMarket cap₹28,104 Cr
P/E (TTM)56.5
EPS (TTM)387.98
Shares outstanding1.29Cr
Listed13 Oct 2008
Ownership
CSVPromoter32.62%
Promoter Δ QoQ-0.01 pp
Public67.38%
FII21.08%
DII16.51%
Pledged2.29%
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 514.3 | 439.7 | 776.3 | 641.6 |
| YoY chg | +65.4% | +10.5% | +136.4% | +119.2% |
| Net profit (₹ Cr) | 96.9 | 40.6 | 212.7 | 147.7 |
| YoY chg | +194.9% | -60.1% | +664.8% | +962.4% |
| Net margin | 18.8% | 9.2% | 27.4% | 23.0% |
| EPS | 75.49 | 31.62 | 165.76 | 115.10 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 32.62% · public 67.38%2021-092026-06
- Promoter
- Public and others
- Promoter
- 32.62%
- Public
- 67.38%
- Promoter change
- -0.01 pp
- Filed
- 20 Jul 2026
- FII
- 21.08%
- DII
- 16.51%
- Promoter pledged
- 2.29%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 417.7 | 392.8 | 385.0 | 439.6 | 310.8 | 398.0 | 328.4 | 292.8 | 514.3 | 439.7 | 776.3 | 641.6 | |
| Other income | 3.0 | 2.1 | 5.4 | 4.8 | 4.3 | 3.9 | 7.5 | 7.9 | 1.8 | 8.1 | 12.5 | 8.5 | |
| Total income | 420.8 | 394.9 | 390.4 | 444.4 | 315.2 | 401.9 | 335.8 | 300.6 | 516.1 | 447.8 | 788.7 | 650.1 | |
| Total expenses | 299.2 | 290.4 | 298.2 | 335.2 | 265.8 | 330.0 | 296.5 | 283.0 | 386.6 | 393.3 | 501.2 | 452.2 | |
| └ Finance costs | 4.4 | 3.7 | 3.6 | 2.7 | 1.1 | 2.2 | 2.3 | 4.6 | 5.4 | 6.8 | 7.2 | 7.0 | |
| └ Depreciation | 14.5 | 15.1 | 16.5 | 16.3 | 16.1 | 16.3 | 16.9 | 20.2 | 22.5 | 23.9 | 25.1 | 26.6 | |
| Profit before tax | 121.6 | 104.5 | 92.2 | 129.8 | 49.4 | 127.8 | 39.3 | 17.6 | 129.4 | 54.5 | 287.5 | 197.8 | |
| Tax expense | 32.3 | 23.1 | 24.6 | 32.0 | 16.6 | 26.2 | 11.5 | 3.7 | 32.6 | 13.9 | 74.8 | 50.2 | |
| Net profit | 89.2 | 81.4 | 67.6 | 97.9 | 32.8 | 101.6 | 27.8 | 13.9 | 96.9 | 40.6 | 212.7 | 147.7 | |
| EPS | 69.56 | 63.44 | 52.66 | 76.28 | 25.60 | 79.18 | 21.67 | 10.83 | 75.49 | 31.62 | 165.76 | 115.10 | |
| Net margin | 21.36% | 20.72% | 17.55% | 22.26% | 10.57% | 25.52% | 8.47% | 4.75% | 18.83% | 9.23% | 27.40% | 23.02% | |
| PBT margin | 29.11% | 26.60% | 23.95% | 29.54% | 15.90% | 32.10% | 11.97% | 6.00% | 25.17% | 12.39% | 37.04% | 30.84% | |
| Tax rate | 26.60% | 22.10% | 26.72% | 24.62% | 33.55% | 20.49% | 29.25% | 20.89% | 25.17% | 25.52% | 26.03% | 25.36% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 5 Aug 2026.
NEULANDLAB at a glance
- NEULANDLAB closed at ₹21,905 on 6 Oct 2026, +0.14% on the day, +56.8% over one year, 9.6% below its 52-week high of ₹24,225.
- Delivery was 51.0% of traded quantity on 6 Oct 2026, the 56th percentile of its own 1,731 sessions with a reading (20-session average 48.6%, 1-year average 37.6%).
- Market capitalisation is ₹28,104 crore at a trailing P/E of 56.5 (trailing EPS ₹387.98).
- Q1 FY27 results (consolidated, filed 5 Aug 2026): revenue ₹642 crore (+119.2% year on year), net profit ₹148 crore (+962.4%); the price moved +8.0% on the first session after.
- Promoters held 32.62% at 30 Jun 2026, down 0.01 percentage points on the previous filing, with 2.29% of promoter shares pledged.
- Q2 FY27 results are expected between 29 Oct 2026 and 10 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE794A01010
SeriesEQ
Listed13 Oct 2008
History from13 Oct 2008
Sessions4,407
Turnover rank#270
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE